Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Tularaemia - Overview
Tularaemia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Tularaemia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tularaemia - Companies Involved in Therapeutics Development
Appili Therapeutics Inc
Aradigm Corp (Ictive)
DynPort Vaccine Company LLC
Emergex Vaccines Holding Ltd
EpiVax Inc
Tularaemia - Drug Profiles
ATI-1701 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ciprofloxacin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NDBR-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Infectious Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SRI-011225 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tularaemia [strain B] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tularaemia vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tularaemia vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tularemia vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tularaemia - Dormant Projects
Tularaemia - Discontinued Products
Tularaemia - Product Development Milestones
Featured News & Press Releases
Sep 15, 2021: MRIGlobal expert co-authors article examining effective methods for Elusive Tularemia Vaccine
Dec 29, 2020: VAXIL provides update on USAMRIID and oral experiments
Jan 28, 2020: Researchers present positive interim data on Appili Therapeutics’ ATI-1701 Biodefense program at 2020 ASM Biothreats
Nov 18, 2019: Researchers present new positive interim data on Appili Therapeutics ATI-1701 biodefense program at 2019 Chemical and Biological Defense Science & Technology Conference
Aug 20, 2019: Researchers to present new data on ATI-1701 at the 2019 Military Health System Research Symposium
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Tularaemia, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Number of Products by Top 10 Targets, 2021
Number of Products by Stage and Top 10 Targets, 2021
Number of Products by Top 10 Mechanism of Actions, 2021
Number of Products by Stage and Top 10 Mechanism of Actions, 2021
Number of Products by Top 10 Routes of Administration, 2021
Number of Products by Stage and Top 10 Routes of Administration, 2021
Number of Products by Top 10 Molecule Types, 2021
Number of Products by Stage and Top 10 Molecule Types, 2021

List of Tables

List of Tables
Number of Products under Development for Tularaemia, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Tularaemia - Pipeline by Appili Therapeutics Inc, 2021
Tularaemia - Pipeline by Aradigm Corp (Inactive), 2021
Tularaemia - Pipeline by DynPort Vaccine Company LLC, 2021
Tularaemia - Pipeline by Emergex Vaccines Holding Ltd, 2021
Tularaemia - Pipeline by EpiVax Inc, 2021
Tularaemia - Dormant Projects, 2021
Tularaemia - Dormant Projects, 2021 (Contd..1)
Tularaemia - Discontinued Products, 2021